Antares pharma to host third quarter 2014 operating and financial
results conference call
Ewing, n.j.--(business wire)--antares pharma, inc. (nasdaq: atrs) today announced it will release its third quarter 2014 financial results before the market opens on thursday, november 6, 2014 and host a conference call at 8:30 a.m. et (eastern time) to discuss the results. eamonn p. hobbs, president and chief executive officer, and robert f. apple, executive vice president, chief operating officer, will host the call. interested parties may participate in the conference call by dialing 1-888-576-4387 (u.s.) or 1-719-325-2432 (international) 5 to 10 minutes prior to the start of the call. the conference access code is 8566591. a replay of the conference call will be available from 11:30 a.m. et on thursday, november 6, 2014 through 11:30 a.m. et on november 21, 2014 by dialing 1-888-203-1112 (u.s.) or 1-719-457-0820 (international), and entering the access code 8566591. an audio web cast and archive of the conference call will also be available under the investor relations section of the antares web site at www.antarespharma.com. about antares pharma antares pharma focuses on self-administered parenteral pharmaceutical products. the company markets otrexup™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. leo pharma markets otrexup™ to dermatologists for adults with severe recalcitrant psoriasis. antares pharma is also developing quickshot® testosterone for testosterone replacement therapy. the company's technology platforms include vibex® disposable medi-jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as tjet® and zomajet® by teva pharmaceutical industries, ltd (teva) and ferring pharmaceuticals (ferring), respectively. antares pharma has a multi-product deal with teva that includes tev-tropin® [somatropin (rdna origin) for injection] human growth hormone (hgh), vibex® epinephrine and several other products. in the u.s. antares has received fda approval for gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by actavis. elestrin® (estradiol gel) is fda approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the u.s. by meda pharma.
ATRS Ratings Summary
ATRS Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission